HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial

Cancer Cell · Published 2026-03-05 · DOI 10.1016/j.ccell.2026.02.006

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ccell.2026.02.006

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy · PHARMACEUTICALS · 2026 · Cites or is cited by this article
• Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study · Journal of Clinical Oncology · 2026 · Cites or is cited by this article
• Precision Warfare in Solid Tumors: Molecular Mechanisms and Emerging Frontiers of Antibody–Drug Conjugates · Immunological Investigations · 2026 · Cites or is cited by this article
• Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth · Cancer Cell · 2026 · Same journal
• Bridging clinical gaps in personalized cancer neoantigen vaccines · Cancer Cell · 2026 · Same journal
• When more target antigen expression is less · Cancer Cell · 2026 · Same journal
• Targeting drug-tolerant persister cells: Let’s bring on the TROPs! · Cancer Cell · 2026 · Same journal
• Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes · Cancer Cell · 2026 · Same journal
• Context dependency in cancer neuroscience · Cancer Cell · 2026 · Same journal
• A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma · Cancer Cell · 2026 · Same journal